RxDoctor Payments Data

Jorge Sotolongo, MD

Obstetrics & Gynecology · Council Bluffs, IANPI 1629189139

Payments from drug & device makers

What this record shows

This record is dominated by other: $170,441 of the $170,676 with a category attached, or 99.9%. Olympus America Inc. accounts for 96.7% of it on its own, with 8 other manufacturers making up the rest. 2023 is the largest year on record at $165,097, more than ten times the $126 reported in 2019. Among obstetrics & gynecology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$170,676in general payments, 2019–2025

Across 19 payments — averaging $8982.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$165K
  • Aesculap, Inc.$5K
  • AbbVie$86
  • Therapeuticsmd, Inc.$49
  • Nalpropion Pharmaceuticals LLC$44
  • Mayne Pharma Commercial LLC$16
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$2350%
  • Other$170,441100%

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$170,676 in reported general payments places this provider in the 95th percentile of 274 obstetrics & gynecology providers in Iowa.

See all obstetrics & gynecology providers in Iowa

Medicare billing

Part B allowed, 2024
$6,832
Medicare patients
25
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol12$11,811
PremarinEstrogens, Conjugated15$4,387
Estradiol88$595
Medroxyprogesterone Acetate39$232
Betamethasone Valerate12$163
Atorvastatin Calcium15$94
Levothyroxine Sodium14$83
Buspirone Hcl13$76
Escitalopram Oxalate11$55
Rosuvastatin Calcium15$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$12$4,38715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 obstetrics & gynecology providers in Iowa.

Other obstetrics & gynecology in Council Bluffs

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →